

Special Issue

Pharmacotherapy and Molecular Biomarkers of Metabolic Diseases

Message from the Guest Editors

Metabolic and cardiovascular diseases, such as type 2 diabetes, dyslipidemia, obesity, hypertension, and heart failure, remain among the leading causes of morbidity and mortality worldwide. These conditions often share overlapping pathophysiological mechanisms and frequently coexist, increasing clinical complexity and risk. Despite advances in pharmacological treatments, significant interindividual variability in drug responses and disease progression persists, highlighting the need for more personalized approaches. This Special Issue aims to present original research at the intersection of pharmacotherapy and molecular biomarker discovery, with the goal of improving the diagnosis, prognosis, and treatment of metabolic and cardiovascular diseases. We invite contributions from clinical and experimental studies, including those addressing genetic, epigenetic, transcriptomic, proteomic, and metabolomic biomarkers, as well as research on pharmacodynamic and pharmacokinetic variability, and precision medicine strategies.

Guest Editors

Dr. Kathleen F. Saavedra Peña

Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile

Dr. Nicolás R. Saavedra Cuevas

Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile

Deadline for manuscript submissions

25 March 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/252161

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)